- Home
- PBFS vs TSHA Comparison
PBFS vs TSHA Comparison
Compare PBFS & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PBFS | TSHA |
|---|---|---|
| Founded | 1889 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 333.8M | 1.8B |
| IPO Year | 2019 | 2020 |
Fundamental Metrics
Financial Performance| Metric | PBFS | TSHA |
|---|---|---|
| Price | $14.54 | $6.82 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $11.63 |
| AVG Volume (30 Days) | 6.8K | ★ 2.7M |
| Earning Date | 05-12-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 36.07 | 5.56 |
| EPS | ★ 0.83 | N/A |
| Revenue | ★ $15,814,000.00 | $9,773,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $1,152.42 |
| P/E Ratio | $17.81 | ★ N/A |
| Revenue Growth | 5.76 | ★ 17.28 |
| 52 Week Low | $11.24 | $2.21 |
| 52 Week High | $15.18 | $7.30 |
Technical Indicators
Market Signals| Indicator | PBFS | TSHA |
|---|---|---|
| Relative Strength Index (RSI) | 55.70 | 65.73 |
| Support Level | $13.74 | $4.39 |
| Resistance Level | $14.70 | N/A |
| Average True Range (ATR) | 0.29 | 0.43 |
| MACD | 0.04 | -0.01 |
| Stochastic Oscillator | 62.90 | 57.56 |
Price Performance
Historical ComparisonAbout PBFS Pioneer Bancorp Inc.
Pioneer Bancorp Inc is involved in providing banking services. These services include Personal services such as Checking, Savings, eBanking Cards, and Business services such as Business Deposit and operating Accounts, Business eBanking, and Business loans. Some of the other services of the company include Government Banking, Wealth Management, Benefits Consulting and Insurance.
About TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a clinical-stage biotechnology company focused on advancing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system, or CNS. The company's clinical program TSHA-102 is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. The Company views its operations and manages its business as a single operating segment, the gene therapy segment, which is the business of developing AAV-based gene therapies for the treatment of rare monogenic diseases of the central nervous system.